These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23803125)

  • 1. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival.
    Nonsrijun N; Mitchai J; Brown K; Leksomboon R; Tuamsuk P
    Asian Pac J Cancer Prev; 2013; 14(5):3331-5. PubMed ID: 23803125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
    Ok Atılgan A; Özdemir BH; Yılmaz Akçay E; Tepeoğlu M; Börcek P; Dirim A
    Ann Diagn Pathol; 2020 Apr; 45():151480. PubMed ID: 32106037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.
    Mehta PB; Jenkins BL; McCarthy L; Thilak L; Robson CN; Neal DE; Leung HY
    Oncogene; 2003 Mar; 22(9):1381-9. PubMed ID: 12618764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between Microvascular Density and Matrix Metalloproteinase 11 Expression in Prostate Cancer Tissues: a Preliminary Study in Thailand.
    Kanharat N; Tuamsuk P
    Asian Pac J Cancer Prev; 2015; 16(15):6639-43. PubMed ID: 26434888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.
    Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ
    Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
    McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
    Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
    Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
    Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
    Schwandner O; Schlamp A; Broll R; Bruch HP
    Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
    Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
    Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
    Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
    Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.
    Babichenko II; Andriukhin MI; Pulbere S; Loktev A
    Int J Clin Exp Pathol; 2014; 7(12):9090-8. PubMed ID: 25674294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
    De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
    Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.